Levothyroxine Sodium* (Levothyroxine Sodium) — Medicare Part D spending
Multiple manufacturers (20) · Rank #81 by total Part D spend · CMS data year 2023
Medicare Part D spent $653,594,902 on Levothyroxine Sodium* (Levothyroxine Sodium) in 2023, the #81 drug by total Part D spending out of 3,598 drugs. That worked out to about $0.25 per dosage unit, $16 per claim and $75 per beneficiary, across 41,684,284 claims for 8,687,969 beneficiaries. Average spending per dosage unit fell -10.2% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Levothyroxine Sodium* (Levothyroxine Sodium) spending at a glance (2023)
| Metric | Levothyroxine Sodium* (Levothyroxine Sodium) |
|---|---|
| Total Part D spending (2023) | $653,594,902 |
| Total spending (2022) | $679,498,030 |
| Year-over-year change in total spending | -3.8% |
| Average spending per dosage unit (2023) | $0.25 |
| Change in spend per dosage unit (YoY) | -10.2% |
| Avg annual change per dosage unit (2019-2023 CAGR) | -8.7% |
| Average spending per claim (2023) | $16 |
| Average spending per beneficiary (2023) | $75 |
| Total claims (2023) | 41,684,284 |
| Beneficiaries (2023) | 8,687,969 |
| Total dosage units (2023) | 2,818,388,144 |
| Manufacturer(s) | Multiple manufacturers (20) |
| National rank by total spend (of 3,598 drugs) | #81 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $679,498,030 | $653,594,902 | -3.8% |
| Avg spend per dosage unit | $0.27 | $0.25 | -10.2% |
| Avg spend per claim | $17 | $16 | — |
| Avg spend per beneficiary | $81 | $75 | — |
| Total claims | 39,097,804 | 41,684,284 | — |
| Beneficiaries | 8,341,730 | 8,687,969 | — |
How Levothyroxine Sodium* compares with nearby drugs
Drugs with total Part D spending closest to Levothyroxine Sodium* (Levothyroxine Sodium):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Levothyroxine Sodium* (Levothyroxine Sodium) (this drug, #81) | $653,594,902 | $0.25 | -10.2% |
| Tivicay (Dolutegravir Sodium) (#79) | $657,133,269 | $74.72 | +6.8% |
| Gabapentin (#80) | $655,916,853 | $0.15 | -6.8% |
| Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) (#82) | $647,548,319 | $23.18 | +1.6% |
| Abilify Maintena (Aripiprazole) (#83) | $636,857,891 | $2,732.27 | +7.0% |
| Dupixent Syringe (Dupilumab) (#84) | $633,292,043 | $966.09 | +6.7% |
Frequently asked questions
How much does Medicare Part D spend on Levothyroxine Sodium*?
Medicare Part D spent $653,594,902 on Levothyroxine Sodium* (Levothyroxine Sodium) in 2023 (the latest CMS data year), across 41,684,284 claims for 8,687,969 beneficiaries. That ranks #81 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Levothyroxine Sodium*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Levothyroxine Sodium* (Levothyroxine Sodium) was $0.25. Compared with 2022 it fell -10.2%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Levothyroxine Sodium*?
CMS attributes Levothyroxine Sodium* (Levothyroxine Sodium) to Multiple manufacturers (20) in the 2023 Part D spending file. Average spending per claim was $16 and per beneficiary $75.
Is the Levothyroxine Sodium* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20